secwatch.observer — SEC 8-K summary
======================================

Issuer:     CLARIVATE PLC (CLVT)
CIK:        0001764046
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001764046-26-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clarivate Q4 revenue $617M, down 7%; pursues LS&H sale; FY26 FCF ~$400M
-----------------------------------------------------------------------

- Q4 net income $3.1M vs loss $191.8M; adjusted EPS $0.20 vs $0.21. Full-year adjusted EBITDA $1,001.8M.
- Organic ACV grew 1.8% in FY2025; recurring revenue mix improved to 88% of total revenue.
- Pursuing sale of Life Sciences & Healthcare; retained Morgan Stanley; proceeds to reduce leverage.
- FY2026 outlook: Adj. EBITDA growth with ~200 bps margin expansion; FCF ~$400M at midpoint.
- Returned $225M to shareholders via share repurchases in 2025 (56M shares).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764046/000176404626000018/0001764046-26-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764046/000176404626000018/clvt-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001764046-26-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer